| 27/12/23 | 07:00:03 | 27 Dec 2023 | | AstraZeneca acquires Gracell |
| 22/12/23 | 07:00:05 | 22 Dec 2023 | | Wainua (eplontersen) granted first US FDA approval |
| 14/12/23 | 15:00:02 | 14 Dec 2023 | | Director/PDMR Shareholding |
| 12/12/23 | 07:05:00 | 12 Dec 2023 | | AstraZeneca to acquire Icosavax |
| 01/12/23 | 15:05:00 | 1 Dec 2023 | | Block listing Interim Review |
| 01/12/23 | 15:00:01 | 1 Dec 2023 | | Total Voting Rights |
| 01/12/23 | 07:00:06 | 1 Dec 2023 | | Discontinuation of two CRYSTALIZE evidence trials |
| 23/11/23 | 15:00:00 | 23 Nov 2023 | | Director/PDMR Shareholding |
| 17/11/23 | 07:00:11 | 17 Nov 2023 | | Truqap approved in US for HR+ breast cancer |
| 14/11/23 | 07:05:01 | 14 Nov 2023 | | Update on PACIFIC-2 Phase III trial for Imfinzi |
| 09/11/23 | 15:00:00 | 9 Nov 2023 | | Director Declaration |
| 09/11/23 | 07:10:01 | 9 Nov 2023 | | Imfinzi combination improves PFS in liver cancer |
| 09/11/23 | 07:05:00 | 9 Nov 2023 | | Agreement with Eccogene for clinical stage GLP-1RA |
| 09/11/23 | 07:00:16 | 9 Nov 2023 | | 9M and Q3 2023 results |
| 01/11/23 | 15:00:00 | 1 Nov 2023 | | Total Voting Rights |
| 01/11/23 | 07:00:12 | 1 Nov 2023 | | AstraZeneca cell & gene therapy deal w/ Cellectis |
| 03/10/23 | 07:00:08 | 3 Oct 2023 | | AstraZeneca settles Nexium liability litigations |
| 02/10/23 | 15:00:02 | 2 Oct 2023 | | Total Voting Rights |
| 22/09/23 | 07:00:04 | 22 Sept 2023 | | Dato-DXd improved PFS in breast cancer |
| 20/09/23 | 07:00:05 | 20 Sept 2023 | | Alexion completes Pfizer gene therapy agreement |
| 15/09/23 | 15:00:01 | 15 Sept 2023 | | Enhertu recommended in EU for HER2-mutant NSCLC |
| 11/09/23 | 16:00:01 | 11 Sept 2023 | | Fasenra Phase III EGPA trial met primary endpoint |
| 06/09/23 | 07:00:06 | 6 Sept 2023 | | Update on US review of Ultomiris for NMOSD |
| 01/09/23 | 15:00:01 | 1 Sept 2023 | | Total Voting Rights |
| 01/08/23 | 15:00:01 | 1 Aug 2023 | | Total Voting Rights |
| 28/07/23 | 07:05:01 | 28 Jul 2023 | | Alexion enters gene therapy agreement with Pfizer |
| 28/07/23 | 07:00:06 | 28 Jul 2023 | | Half-year Report |
| 17/07/23 | 18:10:56 | 17 Jul 2023 | | Beyfortus approved in US for infant RSV prevention |
| 03/07/23 | 15:00:01 | 3 Jul 2023 | | Total Voting Rights |
| 03/07/23 | 07:00:06 | 3 Jul 2023 | | Dato-DXd significantly improved PFS in lung cancer |
| 09/06/23 | 07:05:01 | 9 Jun 2023 | | nirsevimab recommended for infant RSV protection |
| 09/06/23 | 07:00:05 | 9 Jun 2023 | | AstraZeneca agreement with Quell Therapeutics |
| 02/06/23 | 17:00:01 | 2 Jun 2023 | | Imfinzi improved pCR in gastric and GEJ cancers |
| 01/06/23 | 15:05:01 | 1 Jun 2023 | | Block listing Interim Review |
| 01/06/23 | 15:00:03 | 1 Jun 2023 | | Total Voting Rights |
| 01/06/23 | 07:00:10 | 1 Jun 2023 | | Lynparza approved in US for BRCAm prostate cancer |
| 26/05/23 | 07:00:05 | 26 May 2023 | | Imfinzi + Lynparza prolonged PFS in endometrial ca |
| 22/05/23 | 07:05:01 | 22 May 2023 | | Directorate Change |
| 17/05/23 | 07:00:07 | 17 May 2023 | | Tagrisso plus chemo improved PFS in lung cancer |
| 09/05/23 | 11:00:09 | 9 May 2023 | | Director/PDMR Shareholding |
| 09/05/23 | 07:00:16 | 9 May 2023 | | Farxiga extended in the US for heart failure |
| 02/05/23 | 15:00:01 | 2 May 2023 | | Total Voting Rights |
| 02/05/23 | 10:00:02 | 2 May 2023 | | Director/PDMR Shareholding |
| 02/05/23 | 07:00:12 | 2 May 2023 | | ODAC vote on Lynparza combo in prostate cancer |
| 27/04/23 | 17:30:01 | 27 Apr 2023 | | Result of AGM |
| 27/04/23 | 07:05:01 | 27 Apr 2023 | | Board Committee Changes |
| 27/04/23 | 07:00:05 | 27 Apr 2023 | | 1st Quarter Results |
| 26/04/23 | 16:45:01 | 26 Apr 2023 | | Director Declaration |
| 11/04/23 | 07:00:08 | 11 Apr 2023 | | Update to arrangements with Sobi and Sanofi |
| 05/04/23 | 07:00:04 | 5 Apr 2023 | | Lynparza + Imfinzi met endpoint in ovarian cancer |
